Ken Griffin Bellus Health Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2023

May 15, 2023
BUY
$7.14 - $8.53 $30,702 - $36,679
4,300 Added 19.82%
26,000 $187,000
Q4 2022

Feb 14, 2023
SELL
$8.22 - $10.76 $79,734 - $104,372
-9,700 Reduced 30.89%
21,700 $178,000
Q3 2022

Nov 14, 2022
BUY
$8.95 - $12.0 $162,890 - $218,400
18,200 Added 137.88%
31,400 $332,000

Others Institutions Holding BLU

# of Institutions
1
Shares Held
128K
Call Options Held
0
Put Options Held
0
View Full List

About BELLUS Health Inc.

BLU Quotes by TradingView
  • Ticker BLU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,793,000
  • Description
  • BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...
More about BLU
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email